Valuation & Market

A new survey reveals a startling trend: affluent Americans are planning their escape. We dig into the data, from war fears to tax woes, and the "Golden Visas" they're using.

Kardium’s landmark FDA win and a new wave of innovators signal a biotech boom, cementing British Columbia's status as a global hub for health innovation.

A landmark study revealed a chasm between on-screen diversity goals and workplace safety. Now, a new, free training initiative aims to rebuild the culture.

A new guide from the Venture Climate Alliance and HSBC decodes Singapore's 'operational innovation,' revealing a blueprint for scaling climate tech in Southeast Asia.

Ordergroove's new 'Autonomous Subscriptions' platform uses AI agents to optimize revenue and retention, signaling a major shift from manual to intelligent commerce.

With a treasury full of OpenAI equity and the controversial Worldcoin, Eightco (ORBS) offers a risky public market entry into the future of tech.

As layoffs continue, a new guide reveals the critical mistake leaders make: ignoring the employees who stay. Here's how to rebuild trust and retain talent.

Cabana's latest acquisition is more than just expansion; it's a tech-driven strategy to professionalize a $10B industry, one local legacy at a time.

New data reveals a 'Women CEO Effect'—companies led by women don't just break ceilings, they build entirely new pipelines for female leadership.

A landmark deal for Eos's zinc battery tech, backed by Cerberus capital, aims to solve Texas's grid woes and prove a new model for energy storage finance.

Nuwellis bets on educating hundreds of physicians on its Aquadex system, a high-stakes strategy to combat fluid overload and secure its place in medicine.

BioCardia bets its future on Japan's fast-track approval for its heart therapy, a strategic pivot that could unlock global markets or break the bank.

Eason Technology leadership's big share purchase signals confidence. But with declining revenue and a "going concern" warning, is this a bet on a real turnaround?

Shokz's partnership with the Western States 100 isn't just a sponsorship; it's a masterclass in niche marketing. We deconstruct why a market-dominant brand is betting on 369 runners.

Alight's 1-for-20 reverse split aims to save its NYSE listing. Is this a savvy strategic reset or a temporary fix for a stock facing deeper challenges?

A court ruling clears the way for Curium's targeted cancer drug, promising new hope for patients and shaking up the multi-billion-dollar radiopharmaceutical market.

AudioEye appoints Matthew Domeyer as CFO, a strategic move to manage 41 quarters of growth and capitalize on regulatory tailwinds in the booming accessibility market.

Nephros is moving from a product company to a service-based model. We unpack the strategy, financial risks, and why this pivot could redefine its market.

As OMS Energy prepares its FY2026 results, its performance offers a unique window into the future of oil & gas in the pivotal Asia-MENA corridor.

With a fresh $50M, Enhanced Group is selling a future of medically-guided peak performance. But can its controversial Games and peptide platform survive regulatory scrutiny?